EcoDrugPlus

Tubulin Beta 3 Class Iii

Ensembl ID : ENSECRG00000017564
Gene Symbol: TUBB3
2 Cross references
156 Possible Orthologues:

Tubulin Beta 4a Class Iva

Ensembl ID : ENSECRG00000019219
Gene Symbol: TUBB4A
2 Cross references
195 Possible Orthologues:

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSECRG00000017930
Gene Symbol: TUBB4B
3 Cross references
136 Possible Orthologues:

Tubulin Beta Chain-Like

Ensembl ID : ENSECRG00000001209
Gene Symbol: LOC114653605
2 Cross references
196 Possible Orthologues:

Tubulin Beta Chain-Like

Ensembl ID : ENSECRG00000001147
Gene Symbol: LOC114653603
2 Cross references
196 Possible Orthologues:

Tubulin Beta-2b Chain

Ensembl ID : ENSECRG00000001239
Gene Symbol: LOC114653606
2 Cross references
224 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSECRG00000010488
Gene Symbol: TP53
2 Cross references
254 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSECRG00000014980
Gene Symbol: LOC114663144
3 Cross references
192 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSECRG00000003645
Gene Symbol: TYR
3 Cross references
266 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSECRG00000001701
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSECRG00000018110
Gene Symbol: TYK2
3 Cross references
197 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSECRG00000007369
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).